10/646266

10/646266

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspta1623hrr

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 26	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)
NEWS	18	FEB 10	STN Patent Forums to be held in March 2005

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:17:39 ON 10 FEB 2005

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:17:47 ON 10 FEB 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 FEB 2005 HIGHEST RN 828241-21-0
DICTIONARY FILE UPDATES: 9 FEB 2005 HIGHEST RN 828241-21-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\STNEXP4\QUERIES\02102005.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



NODE ATTRIBUTES:

HCOUNT	IS M2	AT	1
HCOUNT	IS M2	AT	2
HCOUNT	IS M1	AT	3
HCOUNT	IS M1	AT	4
HCOUNT	IS M2	AT	6

```
HCOUNT  IS M3     AT   9
HCOUNT  IS M2     AT  10
HCOUNT  IS M3     AT  12
NSPEC   IS C      AT   1
NSPEC   IS C      AT   2
NSPEC   IS C      AT   3
NSPEC   IS C      AT   4
NSPEC   IS C      AT   5
NSPEC   IS C      AT   6
NSPEC   IS C      AT   7
NSPEC   IS C      AT   8
NSPEC   IS C      AT   9
NSPEC   IS C      AT  10
NSPEC   IS C      AT  11
NSPEC   IS C      AT  12
NSPEC   IS C      AT  13
NSPEC   IS C      AT  14
NSPEC   IS C      AT  15
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   1  2  3  4  5  6  7  8  9 10 11 12 13 14 15
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  15

STEREO ATTRIBUTES:
STEREO DEFAULT RELATIVE
NUMBER OF CHIRAL CENTERS IS 1
SS1  REL 7


=> s l1 full
FULL SEARCH INITIATED 16:18:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    520 TO ITERATE

100.0% PROCESSED     520 ITERATIONS                          10 ANSWERS
SEARCH TIME: 00.00.01

L2            10 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               161.33     161.54

FILE 'CAPLUS' ENTERED AT 16:18:37 ON 10 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 10 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 9 Feb 2005 (20050209/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 9 L2

=> d bib abs hitstr 1-9 l3

L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:780756 CAPLUS
DN 141:296928
TI Exchanger for selectively removing counterions from compounds and compounds derived from the methods for pharmaceutical applications
IN Moore, Christine June
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004081073	A2	20040923	WO 2004-IB529	20040223
	WO 2004081073	A3	20041111		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004225150	A1	20041111	US 2004-797350	20040310
PRAI	US 2003-453798P	P	20030311		

AB Compds. derived such as S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine (I) zwitterion with 0-2 molar equivalents of hydrochloride are also disclosed. The chloride removal process was run in batch, but it could easily be run in a plant setting by recirculating the I dihydrochloride solution over an anion exchange resin column or an anion exchange membrane such as Amberlite 400. If the pH is inadvertently raised beyond the desired range, it may easily be adjusted back by adding an appropriate amount of HCl.

IT **404385-39-3**
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)
(exchanger for selectively removing counterions from amino acid compds. suitable for pharmaceutical applications)

RN 404385-39-3 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●2 HCl

L3 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:182830 CAPLUS
DN 140:223311
TI Crystalline solid form of (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
IN Hallinan, Ann E.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018412	A1	20040304	WO 2003-US26347	20030822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004132822	A1	20040708	US 2003-646266	20030822
PRAI	US 2002-405526P	P	20020823		

AB (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid (I) is crystallized as an anhydrous, stoichiometric 1.5 HCl salt and a scaleable crystallization method is disclosed. The salt form was characterized and the absolute configuration of the chiral center was confirmed as I was high melting and appears acceptably nonhygroscopic for use in a pharmaceutical composition Thus, I was prepared in a series of steps starting from 5,5-dihydro-2-pyrone and (Z)-5-tert-butyldimethylsilyloxy-2-penten-1-ol.

IT **404385-91-7P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(crystalline solid form of amino(ethanimidoylamino)methylheptenoic acid)

RN 404385-91-7 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, (2S,5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **404385-39-3P 666748-92-1P 666748-93-2P**
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystalline solid form of amino(ethanimidoylamino)methylheptenoic acid)

RN 404385-39-3 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 666748-92-1 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, hydrochloride, hydrate (2:5:4), (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●5/2 HCl

●2 H_2O

RN 666748-93-2 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, hydrochloride (2:3), (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●3/2 HCl

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:120714 CAPLUS
DN 140:164231
TI Preparation of 2,7-diamino-5-heptenoic acid derivatives for the treatment and prevention of gastrointestinal conditions
IN Manning, Pamela T.; Connor, Jane R.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004012726	A2	20040212	WO 2003-US23324	20030725
	WO 2004012726	A3	20040603		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004127569	A1	20040701	US 2003-626941	20030725
PRAI	US 2002-400660P	P	20020802		

OS MARPAT 140:164231

AB The invention describes therapeutic methods for the prevention and treatment of conditions and diseases of the gastrointestinal tract involving an overprodn. of nitric oxide by inducible nitric oxide synthase (iNOS) by administering a therapeutically effective amount of a selective inhibitor of iNOS. The methods also include the use of selective inhibitors of iNOs in combination with other therapeutic agents, including antimicrobial agents and antisecretory agents. 2,7-Diamino-5-heptenoic acid derivs. R7N:CMeNHCH2CR1:CR2CH2CH2CH(NH2)C(O)J [R1, R2 = H, halo, alkyl, haloalkyl (at least one of R1 or R2 contains halogen); R7 = H, OH; J = OH, alkoxy, NR3R4, where R3 = H, alkyl, alkenyl, alkynyl and R4 = H, (un)substituted heterocyclyl] or their pharmaceutically-acceptable salts are among the compds. claimed. Thus, (2S,5E)-2-amino-6-fluoro-7-[(1-iminoethyl)amino]-5-heptenoic acid dihydrochloride was prepared by a multistep procedure starting from L-glutamic acid and showed IC50 values 0.36, 68, 3.6, and 0.1 μM in hiNOS, hecNOS, hncNOS, and human cartilage assays, resp.

IT **404385-53-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of diaminoheptenoic acid derivs. for treatment and prevention of gastrointestinal conditions)
RN 404385-53-1 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2R,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●2 HCl

≠ Compound

L3 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:931225 CAPLUS
DN 140:5301
TI Preparation of amino acid derivatives and methods for the treatment of respiratory diseases and conditions using a selective inos inhibitor
IN Manning, Pamela T.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 221 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003097163	A2	20031127	WO 2003-US15369	20030516
	WO 2003097163	A3	20041021		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004077639	A1	20040422	US 2003-439669	20030516
PRAI	US 2002-381054P	P	20020516		

OS MARPAT 140:5301
GI



I



II



III

≠ Compounds

AB Compds. I [A = (un)substituted-iminoalkylaminoalkenyl, -iminoalkylaminoalkynyl, -aminoalkylaminoalkylthioalkyl, etc.; B = OH, alkoxy, etc.; R1 and R2 independently = H, alkyl, alkenyl aryl, etc.] and II [R3 = (un)substituted-alkylthio, -alkyloxy, -alkylcarbocyclylalkyl, -nitrogen heterocycle, etc.; X, Y and Z are independently N or substituted C; U = N or substituted C with provision that U is N only when X is N and Z and Y are substituted C; W = N or CH] as well as their pharmaceutically acceptable salts are prepared and claimed as selective inhibitors of inducible nitric oxide synthase. Thus, e.g., III was prepared in eight steps from L-glutamic acid via intermediate coupling of N-Boc protected Me 5-oxopentanoate (preparation given) with tri-Et 2-fluorophosphonoacetate which was followed by hydrolysis, substitution with 3-methyl-1,2,4-oxadiazolin-5-one, acid catalyzed ring cleavage to the iminoethylamine derivative and subsequent deprotection steps. In citrulline assays for human inducible nitric oxide synthesis, I possessed IC50 values of 0.36-197 μM. Therapeutic methods for the prevention and treatment of respiratory diseases or conditions are described, the methods including administering to a subject in need thereof a respiratory disease or condition effective amount of a selective inhibitor of inducible nitric oxide synthase.

IT **404385-39-3P 404385-53-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidates; preparation of amino acid derivs. and methods for the treatment of respiratory diseases and conditions using a selective inducible nitric oxide synthase inhibitor)

RN 404385-39-3 CAPLUS

CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 404385-53-1 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2R,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●2 HCl

IT **404385-91-7P 505098-89-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of amino acid derivs. and methods for the treatment of respiratory diseases and conditions using a selective inducible nitric oxide synthase inhibitor)

RN 404385-91-7 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 505098-89-5 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, (2S,5Z)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404385-91-7
CMF C10 H19 N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:931174 CAPLUS
DN 140:16957
TI Preparation of amino acid derivatives in methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor
IN Manning, Pamela T.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003097050	A2	20031127	WO 2003-US15464	20030516
	WO 2003097050	A3	20040617		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004087653	A1	20040506	US 2003-439679	20030516
PRAI	US 2002-381056P	P	20020516		

OS MARPAT 140:16957
AB The invention claims a combination of an iNOS blocker and a phosphodiesterase (PDE) inhibitor or their pharmaceutically-acceptable salts or prodrugs for the prevention and treatment of respiratory diseases or conditions. The iNOS inhibitors include amino acids HN:CMeNHCH2CHRSCH2CH(NH2)CO2H (R = alkyl, cycloalkyl, hydroxyalkyl, or haloalkyl). Thus, 2S-amino-6-[(1-iminoethyl)amino]-N-(1H-tetrazol-5-yl)hexanamide dihydrochloride (NN) was prepared and shown to be a more potent i-NOS inhibitor (IC50 = 21.4 μM) than 2S-amino-6-[(1-iminoethyl)amino]hexanamide (NIL amide) or NIL dimethylamide. NN is a nicely crystalline product, in contrast to NIL which is a glass and thus

difficult to handle.

IT **404385-39-3P 404385-53-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. in methods for treatment of respiratory diseases with selective iNOS inhibitor and PDE inhibitor)

RN 404385-39-3 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



≠ Salt

●2 HCl

RN 404385-53-1 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2R,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



≠ Salt

●2 HCl

IT **505098-89-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid derivs. in methods for treatment of respiratory diseases with selective iNOS inhibitor and PDE inhibitor)

RN 505098-89-5 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, (2S,5Z)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404385-91-7
CMF C10 H19 N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:261685 CAPLUS
DN 138:287966
TI Preparation of amino acid derivatives as selective nitric oxide synthase inhibitors for ophthalmol. treatment
IN Manning, Pamela T.; Connor, Jane R.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 177 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003026668	A1	20030403	WO 2002-US30213	20020924
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003109522	A1	20030612	US 2001-961816	20010924
	EP 1429777	A1	20040623	EP 2002-761803	20020924
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002012991	A	20040817	BR 2002-12991	20020924
PRAI	US 2001-961816	A	20010924		
	WO 2002-US30213	W	20020924		

OS MARPAT 138:287966
GI



I

AB The acetamidino amino acid derivs. I [R5 = H, or OH; X = CR1:CR2CH2, CR1:CR2, CH2CR1:CR2, C.tplbond.C, CH2C.tplbond.C, C.tplbond.CCH2; R1, R2 = H, halo, alkyl, or haloalkyl; with the proviso that at list one of R1 or R2 contains halo; Z = H, (un)substituted alkyl, alkoxy, or halo; J = H, OH, alkoxy, NR3R4; R3 = H, alkyl, alkenyl, alkynyl; R4 = H, or (un)substituted heterocyclyl] and related 7-iminohexahydro-2-azepinyl derivs. were prepared as selective nitric oxide synthase inhibitors for ophthalmol. treatment. Thus, (2S,5E)-2-amino-6-fluoro-7-[(1-iminoethyl)amino]-5-heptenoic acid dihydrochloride prepared by a multistep procedure starting from L-glutamic acid inhibited the LPS-induced increase in plasma nitrite/nitrate levels with an observed ED50 value of <0.1 mg/kg demonstrating the ability to inhibit inducible nitric oxide synthase activity in vivo.

IT **404385-39-3P 404385-53-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as selective nitric oxide synthase inhibitors for ophthalmol. treatment)

RN 404385-39-3 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 404385-53-1 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2R,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●2 HCl

10/646266

IT **505098-89-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid derivs. as selective nitric oxide synthase inhibitors for ophthalmol. treatment)
RN 505098-89-5 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, (2S,5Z)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404385-91-7
CMF C10 H19 N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:261658 CAPLUS
DN 138:287965
TI Preparation of amino acid derivatives as selective nitric oxide synthase inhibitors for neuroprotective treatment
IN Manning, Pamela T.; Connor, Jane R.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003026638	A1	20030403	WO 2002-US30214	20020924

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003119826 A1 20030626 US 2001-961521 20010924

EP 1429752 A1 20040623 EP 2002-761804 20020924

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI US 2001-961521 A 20010924

WO 2002-US30214 W 20020924

OS MARPAT 138:287965

GI



I

AB The acetamidino amino acid derivs. I [R5 = H, or OH; X = CR1:CR2CH2, CR1:CR2, CH2CR1:CR2, C.tplbond.C, CH2C.tplbond.C, C.tplbond.CCH2; R1, R2 = H, halo, alkyl, or haloalkyl; with the proviso that at least one of R1 or R2 contains halo; Z = H, (un)substituted alkyl, alkoxy, or halo; J = H, OH, alkoxy, NR3R4; R3 = H, alkyl, alkenyl, alkynyl; R4 = H, or (un)substituted heterocyclyl] and related 7-iminohexahydro-2-azepinyl derivs. were prepared as selective nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative conditions. Thus, (2S,5E)-2-amino-6-fluoro-7-[(1-iminoethyl)amino]-5-heptenoic acid dihydrochloride prepared by a multistep procedure starting from L-glutamic acid inhibited the LPS-induced increase in plasma nitrite/nitrate levels with an observed ED50 value of <0.1 mg/kg demonstrating the ability to inhibit inducible nitric oxide synthase activity in vivo.

IT **404385-39-3P 404385-53-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid derivs. as selective nitric oxide synthase inhibitors for treatment of neurodegenerative conditions)

RN 404385-39-3 CAPLUS

CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



●2 HCl

RN 404385-53-1 CAPLUS

CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2R,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



≠ Comp.

●2 HCl

IT **505098-89-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid derivs. as selective nitric oxide synthase inhibitors for treatment of neurodegenerative conditions)
RN 505098-89-5 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, (2S,5Z)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404385-91-7
CMF C10 H19 N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



≠ Comp.

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:754159 CAPLUS
DN 137:263297
TI Preparation of 2,7-diamino-5-heptenoic acid derivatives for the treatment of cancer
IN Manning, Pamela T.; Connor, Jane R.; Seibert, Karen; Rao, Chinthalapally

V.; Reddy, Bandaru S.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 295 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002076395	A2	20021003	WO 2002-US8938	20020321
	WO 2002076395	A3	20040812		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003013702	A1	20030116	US 2001-961969	20010924
	EP 1463495	A2	20041006	EP 2002-717708	20020321
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005500259	T2	20050106	JP 2002-574911	20020321
PRAI	US 2001-278512P	P	20010323		
	US 2001-961969	A	20010924		
	WO 2002-US8938	W	20020321		

OS MARPAT 137:263297

AB Agents and methods for chemoprevention and treatment of neoplasia are described, the agents including a selective inhibitor of inducible nitric oxide synthase and a combination of a selective inhibitor of inducible nitric oxide synthase and an inhibitor of cyclooxygenase-2 in a pharmaceutical composition 2,7-Diamino-5-heptenoic acid derivs. R7N:CMeNHCH2CR1:CR2CH2CH2CH(NH2)C(O)J [R1, R2 = H, halo, alkyl, haloalkyl (at least one of R1 or R2 contains halogen); R7 = H, OH; J = OH, alkoxy, NR3R4, where R3 = H, alkyl, alkenyl, alkynyl and R4 = H, (un)substituted heterocyclyl] or their pharmaceutically-acceptable salts are among the compds. claimed. Thus, (2S,5E)-2-amino-6-fluoro-7-[(1-iminoethyl)amino]-5-heptenoic acid dihydrochloride was prepared by a multistep procedure starting from L-glutamic acid and showed IC50 values 0.36, 68, 3.6, and 0.1 μM in hiNOS, hecNOS, hncNOS, and human cartilage assays, resp.

IT **404385-53-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaminoheptenoic acid derivs. for treatment of cancer)

RN 404385-53-1 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2R,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



≠ Comp.

●2 HCl

L3 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:220540 CAPLUS
DN 136:263465
TI Preparation of 2-amino-2-alkyl-5-heptenoic and -heptynoic acid derivatives useful as nitric oxide synthase inhibitors
IN Hansen, Donald, Jr.; Webber, Ronald Keith; Pitzele, Barnett S.; Sikorski, James; Massa, Mark A.; Hagen, Timothy J.; Grapperhaus, Margaret; Wang, Lijuan Jane; Bergmanis, Arija A.; Kramer, Steven W.; Hallinan, E. Ann
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 216 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022562	A1	20020321	WO 2001-US28673	20010915
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2421504	AA	20020321	CA 2001-2421504	20010915
	AU 2001090883	A5	20020326	AU 2001-90883	20010915
	US 2002132849	A1	20020919	US 2001-953049	20010915
	EP 1317421	A1	20030611	EP 2001-970937	20010915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001013925	A	20030701	BR 2001-13925	20010915
	JP 2004509099	T2	20040325	JP 2002-526762	20010915
	ZA 2003001575	A	20040226	ZA 2003-1575	20030226
	NO 2003001140	A	20030508	NO 2003-1140	20030312
PRAI	US 2000-232683P	P	20000915		
	WO 2001-US28673	W	20010915		

OS MARPAT 136:263465
AB 2-Amino-2-alkyl-5-heptenoic acids derivs. HN:CMeNHCH2CR3:CR2CH2CH2CR1(NH2)CO2H (R1 = alkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl; R2, R3 = H, halo or any group given for R1) and corresponding heptynoic derivs. HN:CMeNHCH2C.tplbond.CCH2CH2CR1(NH2)CO2H were prepared as nitric oxide synthase (NOS) inhibitors. Thus, (2S/5E)-2-amino-2-methyl-6-fluoro-7-[(1-iminoethyl)amino]-5-heptenoic acid dihydrochloride was prepared by a multistep procedure starting with the reaction of tri-Et 2-fluorophosphonoacetate with 3-[(tert-butyldimethylsilyl)oxy]propanal and showed IC50 = 0.4, 37, and 7.6 μM for inhibition of hiNOS, hecNOS, and hncNOS, resp.
IT **404385-39-3P 404385-53-1P 404385-91-7P**

404386-04-5P 404386-20-5P 404386-33-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkylheptenoic and -heptynoic acid derivs. useful as nitric oxide synthase inhibitors)

RN 404385-39-3 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 404385-53-1 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, dihydrochloride, (2R,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 404385-91-7 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 404386-04-5 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 404386-20-5 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, (2R,5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 404386-33-0 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, (2R,5E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **404385-44-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminoalkylheptenoic and -heptynoic acid derivs. useful as nitric oxide synthase inhibitors)
RN 404385-44-0 CAPLUS
CN 5-Heptenoic acid, 2-amino-7-[(1-iminoethyl)amino]-2-methyl-, monohydrochloride, (2S,5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/646266

ALL CITATIONS AVAILABLE IN THE RE FORMAT